The 3 most recent market catalysts affecting $GTBP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 75
GT Biopharma shares are trading lower. The company announced IND clearance from the FDA for GTB-5550 in multiple myeloma.
The headline presents a classic 'buy the rumor, sell the news' scenario, or indicates that the market perceives the IND clearance as insufficient to overcome other negative pressur…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 85
EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
GT Biopharma announced FDA IND clearance for its multiple myeloma drug, GTB-5550, enabling the initiation of Phase 1a/1b human trials. This is a crucial de-risking event for the co…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 92
GT Biopharma Q2 EPS $(0.12) Misses $(0.08) Estimate
GT Biopharma (GTBP) announced Q2 earnings with a loss of $(0.12) per share, which was 50% worse than the analyst consensus estimate of $(0.08). This significant miss indicates that…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.